STAAR Surgical board recommends $28 per share Alcon merger

STAAR Surgical Company (NASDAQ: STAA) filed definitive proxy materials with the Securities and Exchange Commission for its pending merger with Alcon (SIX/NYSE: ALC). The company will hold a special meeting of stockholders on October 23 at 8:30 a.m. Pacific Time to vote on the merger agreement.

The STAAR board unanimously recommends stockholders vote in favor of the $28.00 per share cash offer from Alcon. According to the company, this represents approximately a 51% premium to the closing stock price the day prior to the announcement and a 59% premium to the 90-day volume-weighted average price.

STAAR's stock closed at $18.49 per share just before the merger announcement on August 5, 2025. The company stated the merger value exceeds what it could achieve independently due to its lower growth rate and competitive challenges in its markets, particularly exposure to China where sales trends have declined.

Stockholders of record as of September 12, 2025 are entitled to vote at the meeting. The merger requires approval from holders of a majority of STAAR's outstanding common stock. Failure to vote will count as a vote against the proposal.

STAAR manufactures implantable phakic intraocular lenses for vision correction and has sold more than 3 million implantable collamer lenses in over 75 countries. The company is headquartered in Lake Forest, California.

You May Also Be Interested In